Ignite Creation Date:
2025-12-24 @ 7:52 PM
Ignite Modification Date:
2026-01-04 @ 8:13 AM
Study NCT ID:
NCT01788904
Status:
UNKNOWN
Last Update Posted:
2013-12-12
First Post:
2013-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Plasma i-FABP as Predictor for Irreversible Bowel Ischemia
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood plasma, blood serum, EDTA blood'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 24}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2013-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-12', 'completionDateStruct': {'date': '2017-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2013-12-11', 'studyFirstSubmitDate': '2013-02-07', 'studyFirstSubmitQcDate': '2013-02-08', 'lastUpdatePostDateStruct': {'date': '2013-12-12', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2013-02-11', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Levels of i-FABP, interleukine 6 and 8', 'timeFrame': '72 hours', 'description': 'Association of increased levels of i-FABP, interleukine 6 and 8 with extension of intestinal necrosis according to the pathology report and occurrence of organ failure'}], 'primaryOutcomes': [{'measure': 'Post-interventional course of plasmatic i-FABP as reliable predictor for successful bowel revascularization', 'timeFrame': '72 hours', 'description': 'Subjects will be observed for 72 hours after percutaneous revascularization. Patients will then be divided into two groups: patients not requiring surgery and not dying from intestinal necrosis will be allocated to group A. Subjects who undergo surgery without signs of necrotic segments will also be attributed to group A. Patients in whom intestinal necrosis is confirmed by surgery or autopsy will belong to group B.\n\nTo evaluate whether the post-interventional course of plasmatic i-FABP is a reliable predictor for successful revascularization, the minimum level of i-FABP at the time points 5, 30 and 120 Minutes is divided by the baseline (= before intervention) level of i-FABP. This ratio (R) reflects the decrease (or increase) of i-FABP after revascularization. ROC-analysis will be carried out and the area under the curve will be determined for different R-values.'}], 'secondaryOutcomes': [{'measure': 'Baseline level of i-FABP as predictor of bowel necrosis', 'timeFrame': '72 hours'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Acute mesenteric ischemia', 'Percutaneous endovascular revascularization', 'Intestinal plasma fatty acid binding protein (i-FABP)', 'Bowel necrosis'], 'conditions': ['Acute Mesenteric Ischemia', 'Bowel Necrosis']}, 'descriptionModule': {'briefSummary': 'In the FARAMIS study, we aim to investigate the longitudinal course of intestinal plasma fatty acid binding protein (i-FABP) in patients with acute mesenteric ischemia (AMI) undergoing primary percutaneous angiographic intervention.\n\nThe investigators postulate that patients with fully re-established intestinal blood flow and vital intestines will display a significant drop of plasmatic i-FABP within 24 hours, while patients requiring subsequent intestinal resection due to irreversible bowel necrosis will not.\n\nIf true, patients requiring laparotomy and bowel resection could be identified and patients in whom angiographic intervention led to successful cure of disease would not be exposed to potentially perilous surgery.', 'detailedDescription': 'Intestinal plasma fatty acid binding proteins (i-FABP) have been introduced as a powerful marker for the diagnosis of intestinal ischemia. Based on several small studies, this marker is referred to as a sensitive indicator for intestinal ischemia. I-FABP is characterized by its short half-time of eleven minutes in blood circulation, which might allow "real-time" monitoring of necrotic intestinal segments.\n\nSubjects meeting the in-/exclusion criteria will undergo five to six blood collections: one baseline assessment before revascularization, three assessments directly after angiographic intervention (5/30/120 minutes), and one assessment after 24 hours. An additional blood collection will be performed in patients who underwent subsequent surgery. In addition, clinical exams of the patient are carried out.\n\nSubjects will be observed for 72 hours after percutaneous revascularization and retrospectively classified depending on the clinical course: recovering patients or patients undergoing surgery without signs of necrotic segments will be attributed to group A. Patients in whom intestinal necrosis is confirmed by surgery or autopsy will belong to group B. For all patients, clinical and laboratory findings will be reported in a descriptive manner.\n\nTo evaluate whether the post-interventional course of plasmatic i-FABP is a reliable predictor for successful revascularization, the minimum level of i-FABP at the time points 5, 30 and 120 Minutes is divided by the baseline (= before intervention) level of i-FABP. This ratio (R) reflects the decrease (or increase) of i-FABP after revascularization. Receiver operating characteristic (ROC)-analysis will be carried out and the area under the curve will be determined for different R-values (e.g. 0.3, 0.5, 0.7).\n\nWe postulate that patients with fully re-established intestinal blood flow and vital intestines will display a significant drop of plasmatic i-FAPB within 24 hours, while patients requiring subsequent intestinal resection due to irreversible bowel necrosis will not.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Tertiary care clinic', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Presence of acute mesenteric ischemia due to stenosis of the superior mesenteric artery, thromboembolization of the superior mesenteric artery, non-occlusive mesenteric ischemia or acute portal vein thrombosis (as confirmed by CT scan)\n* The vascular anatomy is suitable for percutaneous revascularization\n* A primary endovascular re-vascularisation approach is intended based on an interdisciplinary decision by the visceral surgeon, the vascular surgeon and interventional radiologist. This therapeutic decision is made independently of the proposed FARAMIS study.\n* A peripheral or central line is present to perform repeated blood collections\n\nExclusion Criteria:\n\n* Clinically or imaging results indicating that perforation of the bowel is present or suspected\n* Hemodynamic instability (shock)\n* Pre-existing severe liver or kidney damage (defined as spontaneous international normalized ratio \\>2 or creatinine \\>2 mg/dl.)\n* Anemia with hemoglobin concentration \\< 7g/dl\n* Pediatric patients'}, 'identificationModule': {'nctId': 'NCT01788904', 'acronym': 'FARAMIS', 'briefTitle': 'Plasma i-FABP as Predictor for Irreversible Bowel Ischemia', 'organization': {'class': 'OTHER', 'fullName': 'University Hospital Regensburg'}, 'officialTitle': 'Plasma i-FABP as Predictor for Irreversible Bowel Ischemia After Interventional Re-vascularization in Patients With Acute Mesenteric Ischemia', 'orgStudyIdInfo': {'id': 'FARAMIS 2013'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patients with acute mesenteric ischemia', 'description': 'Patients with acute mesenteric ischemia meeting the in-/exclusion criteria'}]}, 'contactsLocationsModule': {'locations': [{'zip': '93053', 'city': 'Regensburg', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Philipp Renner, MD', 'role': 'CONTACT', 'email': 'philipp.renner@ukr.de', 'phone': '+49 151 1944 5787'}, {'name': 'Peter Heiss, MD', 'role': 'CONTACT', 'email': 'peter.heiss@ukr.de', 'phone': '+49 941 944 7401'}, {'name': 'Peter Heiss, MD, MS', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Philipp Renner, MD', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'University Hospital Regensburg', 'geoPoint': {'lat': 49.01513, 'lon': 12.10161}}], 'centralContacts': [{'name': 'Peter G Heiss, MD, MS', 'role': 'CONTACT', 'email': 'peter.heiss@ukr.de', 'phone': '+49 941 944 7401'}, {'name': 'Philipp Renner, MD', 'role': 'CONTACT', 'email': 'philipp.renner@ukr.de', 'phone': '+49 151 1944 5787'}], 'overallOfficials': [{'name': 'Peter Heiss, MD, MS', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Hospital Regensburg Germany'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University Hospital Regensburg', 'class': 'OTHER'}, 'collaborators': [{'name': 'William Cook Europe', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Peter Heiss, MD, MS', 'investigatorFullName': 'Peter Heiss', 'investigatorAffiliation': 'University Hospital Regensburg'}}}}